Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic
Article
Published on
Journal: American journal of obstetrics & gynecology MFM [Category] COVID19(2023년), SARS, 임상, 진단,
Journal: American journal of obstetrics & gynecology MFM [Category] COVID19(2023년), SARS, 임상, 진단,
[키워드] administration
Admission
adverse events
anaphylaxis
Atlanta
authorization
benefit
casirivimab and imdevimab
Clinical course
Clinical outcome
Cohort
cohort of patient
COVID-19
COVID-19 illness
COVID-19 pandemic
COVID-19 therapeutics
death
drug
Effect
Efficacy
eligible
Emergency
food
groups
high-risk population
higher risk
Hospital stay
Hospitalization
Hypothesis
increased risk
individual
Infection
instance
intensive care
less
Maternal morbidity
Memorial
monoclonal antibodies
monoclonal antibody
morbidity and mortality
need for oxygen
Neonatal
Neonatal morbidity
no significant difference
nonpregnant
novel therapies
offered
outcome
outcomes
Oxygen requirement
patients with SARS-CoV-2
pharmacologic treatment
Placebo
polymerase chain
positive
Pregnancy
pregnant
pregnant patient
pregnant patients
pregnant population
receive
reduce
reduced
REGEN-COV
released
resolved
Respiratory illness
retrospective cohort study
risk
Safe
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 viral load
severe COVID-19
severe disease
Shortness of breath
shown
side
statistically significant difference
Symptom
tested
therapy
thought
treated
Treatment
treatment guideline
Trial
trials
ventilatory support
were excluded
worsening
[DOI] 10.1016/j.ajogmf.2022.100673 [Article Type] Article
[DOI] 10.1016/j.ajogmf.2022.100673 [Article Type] Article